Shares of AngioDynamics ANGO were unchanged after the company reported Q4 results.
Quarterly Results
Earnings per share fell 124.00% over the past year to ($0.06), which were in line with the estimate of ($0.06).
Revenue of $58,332,000 declined by 39.43% year over year, which missed the estimate of $64,300,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
AngioDynamics hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: Jul 16, 2020
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/hq97nqzr
Recent Stock Performance
Company's 52-week high was at $21.90
Company's 52-week low was at $7.48
Price action over last quarter: Up 7.39%
Company Profile
AngioDynamics Inc designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.